SAN MATEO, Calif. — September 10, 2025 — Leads & Copy — Sagimet Biosciences Inc. (Nasdaq: SGMT) will present at the 9th Annual MASH Drug Development Summit from Sept. 29-Oct. 1, 2025, in Boston, MA. The presentations will cover combination treatment with a FASN inhibitor and AI-based digital pathology to evaluate denifanstat’s anti-fibrotic effect in MASH patients.
Marie O’Farrell, Ph.D., Senior Vice President of Research and Development, will highlight the mechanism of action of FASN Inhibitor Denifanstat in MASH. The presentation will focus on reviewing the preclinical activity of a FASN inhibitor combined with semaglutide or resmetirom and will highlight the efficacy of denifanstat when added to background GLP1 treatment in the Phase 2b FASCINATE-2 study. Dr. O’Farrell will also cover the planned Phase 1 PK study of denifanstat and resmetirom.
Dr. O’Farrell will also present at a panel discussion: Designing Therapies with Novel Mechanisms & Predictive Biomarkers to Holistically Improve Treatment for Better Patient Outcomes.
Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences, will discuss utilizing AI-Based Digital Pathology to Evaluate Denifanstat’s Anti-Fibrotic Effect in MASH Patients with Advanced Fibrosis. This presentation will discuss the mechanism of action for denifanstat and its robust anti-fibrotic effect in MASH patients with F3 fibrosis as well as the application of digital pathology techniques to assess this anti-fibrotic effect. Dr. Tsai will also discuss the use of zonal analysis to explore denifanstat’s potential to offer long-term clinical benefit.
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH).
FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S.
MASH is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there are few approved treatments.
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Source: Sagimet Biosciences
